ABT vs AEE Stock Comparison

Scores Breakdown

Metric	ABT	AEE
📈 Growth	22/30	0/30
💰 Profitability	17/20	12/20
🏦 Financial Health	15/20	14/20
💵 Valuation	12/20	12/20
⚠️ Risk (lower is better)	4/10	7/10
Overall Score	72/100	41/100

Side-by-Side Summaries

ABT Analysis	AEE Analysis
📈 Growth & Financial Trajectory Over the 8-quarter window, Revenue gravitated around $9.96B to $11.16B, ending at $11.16B in 2026 Q1, a start-to-end rise of about $1.2B (~12%). Net income remained positive through most quarters, with modest-to-strong fluctuations; several quarters show mid-single-digit billions in income, with notable variability from one-off items (e.g., tax effects). 💰 Margins & Cash Flow Gross Margin was solid, around 56% on average (Gross Profit ~6.3B vs Revenues ~11.2B in 2026 Q1). Operating margin ranged roughly from 12% to 18%, peaking in 2025 Q2. Net cash flow from operating activities was consistently positive (e.g., 2026 Q1: $1.315B; prior quarters in the 1.4–2.9B range), while investing activities were typically cash outflows and financing modest. 🛡️ Balance Sheet & Liquidity Total assets approximate $72B–$110B over the period with equity in the low-to-mid $50B range. The company shows a healthy current ratio (~~1.3–1.5) and modest long-term debt (~~$14–19B), supporting liquidity and balance sheet resilience. ⚠️ Key Drivers & Risks Drivers: (1) Pharma/medical devices demand; (2) diversified product mix and recurring revenue from Rx/OTC portfolios. Risks: (1) Regulatory/tax volatility and pricing pressure; (2) macro-cycle sensitivity and currency exposure.	📈 Growth & Financial Trajectory Over eight quarters, Ameren's revenue progressed from $2.173B in 2024 Q2 to $2.176B in 2026 Q1, essentially flat. A standout spike occurred in 2025 Q3 at $2.699B, followed by a dip to $1.782B in 2025 Q4, then a return toward $2.2B. Net income moved unevenly, starting at $457M (Q2 2024) and ending at $358M (Q1 2026), with a peak of $640M in 2025 Q3. 💰 Margins & Cash Flow Operating margins fluctuated, averaging around 24.6%, peaking at 39.3% (2025 Q1) and dipping to 10.2% (2024 Q4). Cash flow: net cash from operating activities was generally positive; investing activities were typically negative, and financing activity provided offsetting support in several quarters. The quarterly cadence yields solid operating cash flow in aggregate, aligning with a capital-intensive utility model. 🛡️ Balance Sheet & Liquidity Total assets run near $49.8B with liabilities around $36.2B and equity of about $13.6B. Long-term debt sits near $19.4B, indicating a moderate debt load for a regulated utility. The balance sheet remains constructive, supported by recurring operating cash flows. ⚠️ Key Drivers & Risks Drivers: Regulated utility framework and stable dividend policy; cash-flow visibility from rate cases. Risks: Regulatory changes and weather-driven demand variability; interest-rate and valuation sensitivity.

ABT Analysis

AEE Analysis

📈 Growth & Financial Trajectory

Over the 8-quarter window, Revenue gravitated around $9.96B to $11.16B, ending at $11.16B in 2026 Q1, a start-to-end rise of about $1.2B (~12%). Net income remained positive through most quarters, with modest-to-strong fluctuations; several quarters show mid-single-digit billions in income, with notable variability from one-off items (e.g., tax effects).

💰 Margins & Cash Flow

Gross Margin was solid, around 56% on average (Gross Profit ~6.3B vs Revenues ~11.2B in 2026 Q1). Operating margin ranged roughly from 12% to 18%, peaking in 2025 Q2. Net cash flow from operating activities was consistently positive (e.g., 2026 Q1: $1.315B; prior quarters in the 1.4–2.9B range), while investing activities were typically cash outflows and financing modest.

🛡️ Balance Sheet & Liquidity

Total assets approximate $72B–$110B over the period with equity in the low-to-mid $50B range. The company shows a healthy current ratio (~~1.3–1.5) and modest long-term debt (~~$14–19B), supporting liquidity and balance sheet resilience.

⚠️ Key Drivers & Risks

Drivers: (1) Pharma/medical devices demand; (2) diversified product mix and recurring revenue from Rx/OTC portfolios.
Risks: (1) Regulatory/tax volatility and pricing pressure; (2) macro-cycle sensitivity and currency exposure.

📈 Growth & Financial Trajectory

Over eight quarters, Ameren's revenue progressed from $2.173B in 2024 Q2 to $2.176B in 2026 Q1, essentially flat. A standout spike occurred in 2025 Q3 at $2.699B, followed by a dip to $1.782B in 2025 Q4, then a return toward $2.2B. Net income moved unevenly, starting at $457M (Q2 2024) and ending at $358M (Q1 2026), with a peak of $640M in 2025 Q3.

💰 Margins & Cash Flow

Operating margins fluctuated, averaging around 24.6%, peaking at 39.3% (2025 Q1) and dipping to 10.2% (2024 Q4). Cash flow: net cash from operating activities was generally positive; investing activities were typically negative, and financing activity provided offsetting support in several quarters. The quarterly cadence yields solid operating cash flow in aggregate, aligning with a capital-intensive utility model.

🛡️ Balance Sheet & Liquidity

Total assets run near $49.8B with liabilities around $36.2B and equity of about $13.6B. Long-term debt sits near $19.4B, indicating a moderate debt load for a regulated utility. The balance sheet remains constructive, supported by recurring operating cash flows.

⚠️ Key Drivers & Risks

Drivers: Regulated utility framework and stable dividend policy; cash-flow visibility from rate cases.
Risks: Regulatory changes and weather-driven demand variability; interest-rate and valuation sensitivity.

Similar Companies

ABBV Score: 59 BSX Score: 81 ELV Score: 77 ISRG Score: 85 JNJ Score: 79 MDT Score: 67 TMO Score: 75 TSLA Score: 62

Top Rated Companies

View Top 20 →

MU "MICRON TECHNOLOGY INC"

AVGO "Broadcom Inc."

KMI "KINDER MORGAN, INC."

MNST "Monster Beverage Corp"

NEM "NEWMONT Corp /DE/"